While this panel has grown in recent years, many experts believe additional biomarkers should also be incorporated as ...

The FDA accepted a new drug application for zidesamtinib for previously treated locally advanced or metastatic ROS1-positive ...

The accelerated FDA approval of Bayer's Hyrnuo covers treatment of advanced cases of non-small cell lung cancer with HER2 ...

The U.S. Food and Drug Administration said on Wednesday that it has approved Bayer's drug for patients with a form of lung ...

Discover why Rigel Pharma (RIGL) is a contrarian biotech BUY with surging revenues, strong drug sales, and 20-30% upside ...

Black Diamond Therapeutics remains undervalued despite recent share price gains, with a promising EGFR inhibitor pipeline ...

In patients naïve to HER2-targeted therapy, the objective response rate was 71% with a median duration of response of 9.2 months.

The Food and Drug Administration granted accelerated approval on Wednesday for a new drug developed by researchers at the ...

Zidesamtinib targets ROS1+ NSCLC patients with prior TKI treatment, addressing CNS-penetrant treatment challenges and ...

Berlin: Bayer has received accelerated approval from the U.S. Food and Drug Administration (FDA) for HYRNUO ...

Bayer’s Hyrnuo gets US FDA accelerated approval to treat patients with previously treated advanced HER2-mutant NSCLC: Berlin Friday, November 21, 2025, 11:00 Hrs [IST] Following ...

FDA grants accelerated approval to Bayer's Hyrnuo and full approval to Amgen's Imdelltra, expanding treatment options for ...